Vaccines - Greece

Greece

The Vaccines market in Greece is expected to achieve a revenue of US$170.10m by 2024.
It is projected to display a steady annual growth rate of -3.75% from 2024 to 2029, leading to a market volume of US$140.50m by 2029.
When compared globally, United States is anticipated to generate the highest revenue of US$29,120.00m in 2024.
Greece is seeing an increasing demand for vaccines as the government focuses on improving public health.

Key regions: Australia, Italy, France, South Korea, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The Vaccines market in Greece has been developing at a steady pace in recent years, driven by various factors that have contributed to its growth.

Customer preferences: Greece has a high vaccination rate, with the majority of the population being vaccinated against common diseases such as measles, mumps, and rubella. The COVID-19 pandemic has also led to an increase in demand for vaccines in the country, with many Greeks opting to get vaccinated to protect themselves and their families.

Trends in the market: One of the key trends in the Vaccines market in Greece is the growing demand for vaccines that target specific diseases. For instance, there has been an increase in the demand for vaccines that target cancer, as well as vaccines that are designed to prevent certain types of infections.

Local special circumstances: Greece has a well-established healthcare system that provides access to vaccines for all its citizens. The government has also been proactive in promoting vaccination campaigns, with various initiatives aimed at raising awareness about the importance of vaccination.

Underlying macroeconomic factors: The Greek economy has been recovering in recent years, following a period of economic instability. This has led to an increase in healthcare spending, with more funds being allocated towards the purchase of vaccines. Additionally, the country's aging population has also contributed to the growth of the Vaccines market in Greece, with older individuals being more susceptible to certain diseases and infections. In conclusion, the Vaccines market in Greece has been growing steadily in recent years, driven by various factors such as high vaccination rates, growing demand for disease-specific vaccines, a well-established healthcare system, and an aging population. With the ongoing COVID-19 pandemic, the demand for vaccines is expected to remain strong in the coming years, further boosting the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.